JP5132554B2 - Ｔｐｏ模倣剤としてのヘテロ四環化合物 - Google Patents

Ｔｐｏ模倣剤としてのヘテロ四環化合物 Download PDF

Info

Publication number
JP5132554B2
JP5132554B2 JP2008521705A JP2008521705A JP5132554B2 JP 5132554 B2 JP5132554 B2 JP 5132554B2 JP 2008521705 A JP2008521705 A JP 2008521705A JP 2008521705 A JP2008521705 A JP 2008521705A JP 5132554 B2 JP5132554 B2 JP 5132554B2
Authority
JP
Japan
Prior art keywords
alkyl
halo
substituted
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008521705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501728A (ja
Inventor
フィリップ・ビー・アルパー
トーマス・マーシルジェ
アーナブ・チャッタージー
ウェンシュオ・ル
ダニエル・マットニック
マイケル・ジェイ・ロバーツ
ユン・ヘ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of JP2009501728A publication Critical patent/JP2009501728A/ja
Application granted granted Critical
Publication of JP5132554B2 publication Critical patent/JP5132554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
    • C08J7/04—Coating
    • C08J7/042—Coating with two or more layers, where at least one layer of a composition contains a polymer binder
    • C08J7/0423—Coating with two or more layers, where at least one layer of a composition contains a polymer binder with at least one layer of inorganic material and at least one layer of a composition containing a polymer binder
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2369/00—Characterised by the use of polycarbonates; Derivatives of polycarbonates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
JP2008521705A 2005-07-14 2006-07-14 Ｔｐｏ模倣剤としてのヘテロ四環化合物 Expired - Fee Related JP5132554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69948105P 2005-07-14 2005-07-14
US60/699,481 2005-07-14
PCT/US2006/027691 WO2007009120A2 (en) 2005-07-14 2006-07-14 Heterotetracyclic compounds as tpo mimetics

Publications (2)

Publication Number Publication Date
JP2009501728A JP2009501728A (ja) 2009-01-22
JP5132554B2 true JP5132554B2 (ja) 2013-01-30

Family

ID=37638014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008521705A Expired - Fee Related JP5132554B2 (ja) 2005-07-14 2006-07-14 Ｔｐｏ模倣剤としてのヘテロ四環化合物

Country Status (16)

Country Link
US (1) US8153671B2 (zh)
EP (1) EP1910338B1 (zh)
JP (1) JP5132554B2 (zh)
KR (1) KR20080028929A (zh)
CN (1) CN101213190A (zh)
AT (1) ATE478863T1 (zh)
AU (1) AU2006267077A1 (zh)
BR (1) BRPI0613460A2 (zh)
CA (1) CA2612442A1 (zh)
DE (1) DE602006016449D1 (zh)
ES (1) ES2351455T3 (zh)
MX (1) MX2008000462A (zh)
PL (1) PL1910338T3 (zh)
PT (1) PT1910338E (zh)
RU (1) RU2008105071A (zh)
WO (1) WO2007009120A2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
SG10201402969QA (en) * 2009-03-27 2014-09-26 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
EP2305688A1 (en) 2009-09-28 2011-04-06 Université de la Méditerranée - Aix-Marseille II Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
NZ627188A (en) 2012-01-27 2015-12-24 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
ES2788977T3 (es) 2014-04-22 2020-10-23 Univ Montreal Compuestos y uso de los mismos en la expansión de células madre hematopoyéticas y/o células progenitoras hematopoyéticas
CN106724598B (zh) * 2017-02-28 2017-11-24 宁波圆明工业设计有限公司 一种含有滤料的水杯
IT201700100116A1 (it) * 2017-09-07 2019-03-07 Univ Pisa Composti a struttura benzo[a]carbazolica e loro usi
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6256471A (ja) 1985-09-05 1987-03-12 Teikoku Hormone Mfg Co Ltd 含窒素四環式化合物
JPS62147462A (ja) 1985-12-20 1987-07-01 Canon Inc 電子写真感光体
JPS63148267A (ja) 1986-12-12 1988-06-21 Canon Inc 電子写真感光体
SE8902273D0 (sv) * 1989-06-22 1989-06-22 Univ Cincinnati Indenoindole compounds i
SE8902274D0 (sv) 1989-06-22 1989-06-22 Univ Cincinnati Indenoidole compounds ii
JPH06228554A (ja) 1993-02-04 1994-08-16 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子
TW430660B (en) 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
JPH11322756A (ja) 1998-03-17 1999-11-24 Nippon Soda Co Ltd ベンゾチオピラノインドール化合物および農園芸用殺菌剤
US6288099B1 (en) * 1998-12-04 2001-09-11 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
AU2163600A (en) 1998-12-04 2000-06-26 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
JP4093448B2 (ja) 1999-01-11 2008-06-04 アグロン・ファーマシューティカルズ・インコーポレーテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
AU2079901A (en) * 1999-12-06 2001-06-12 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
CN101072780B (zh) * 2004-09-20 2010-06-23 詹森药业有限公司 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物

Also Published As

Publication number Publication date
MX2008000462A (es) 2008-03-10
PL1910338T3 (pl) 2011-02-28
KR20080028929A (ko) 2008-04-02
PT1910338E (pt) 2010-12-02
ATE478863T1 (de) 2010-09-15
JP2009501728A (ja) 2009-01-22
WO2007009120A2 (en) 2007-01-18
AU2006267077A1 (en) 2007-01-18
BRPI0613460A2 (pt) 2011-01-11
US20090075996A1 (en) 2009-03-19
WO2007009120A3 (en) 2007-05-03
US8153671B2 (en) 2012-04-10
CN101213190A (zh) 2008-07-02
RU2008105071A (ru) 2009-08-20
DE602006016449D1 (zh) 2010-10-07
ES2351455T3 (es) 2011-02-04
EP1910338B1 (en) 2010-08-25
CA2612442A1 (en) 2007-01-18
EP1910338A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
JP5132554B2 (ja) Ｔｐｏ模倣剤としてのヘテロ四環化合物
US20220112159A1 (en) Sulfonylureas and related compounds and use of same
US7816542B2 (en) Compounds and compositions as TPO mimetics
CA2938280C (en) 4-amino-imidazoquinoline compounds
JP6422438B2 (ja) ＲＯＲγＴ阻害剤としての４−ヘテロアリール置換安息香酸化合物およびその使用
TW201125865A (en) Oxadiazole derivative having inhibion activity on endothelial lipase
JPWO2010035745A1 (ja) ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2010524913A (ja) 炎症治療において有用なピラゾール
JP2012072068A (ja) 二環式へテロ環化合物
WO2010041711A1 (ja) イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JPH0859621A (ja) 置換キノリン誘導体、それらの製造方法およびそれらの使用
JP5807308B2 (ja) ピリミドベンゾチアジン−６−イミン誘導体またはその塩を含有するウイルス感染症の治療および／または予防のための薬剤
RU2795512C2 (ru) Сульфонилмочевины и родственные соединения и их применение
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
JP2022550393A (ja) Ｂ型肝炎ウイルス感染の処置及び予防のための置換３，４－ジヒドロキナゾリン
TW202412770A (zh) 用於治療ｔｒｐｍ３介導之病症的吲口巾衍生物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121009

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121106

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151116

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees